title: Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.
abstract: OBJECTIVE
  Developing a parameter to predict bone marrow invasion by non-Hodgkin's lymphoma is an important unmet medical need for treatment decisions. This study aimed to confirm the validity of the hypothesis that bone marrow plasma vascular endothelial growth factor level might be correlated with the risk of bone marrow involvement and the prognosis of patients with diffuse large B-cell non-Hodgkin's lymphoma.
  
  
  METHODS
  Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled. Vascular endothelial growth factor level was measured with enzyme-linked immunosorbent assay. The validity of bone marrow plasma vascular endothelial growth factor level and bone marrow vascular endothelial growth factor level per platelet count for predicting treatment response and survival after initial rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone combined chemotherapy was assessed.
  
  
  RESULTS
  Bone marrow plasma vascular endothelial growth factor level per platelet count was significantly associated with old age (≥ 65 years), poor performance score (≥ 2), high International prognosis index (≥ 3) and bone marrow invasion. The patients with high bone marrow plasma vascular endothelial growth factor level per platelet count (≥ 3.01) showed a significantly lower complete response rate than the others. On Kaplan-Meier survival curves, the patients with high bone marrow plasma vascular endothelial growth factor levels (≥ 655 pg/ml) or high bone marrow plasma vascular endothelial growth factor level per platelet count (≥ 3.01) demonstrated a significantly shorter overall survival and progression-free survival than the others. In the patients without bone marrow involvement, bone marrow plasma vascular endothelial growth factor level per platelet count had a significant relationship with overall survival and progression-free survival. Multivariate analysis revealed that the patients without BM invasion showing high level of bone marrow plasma vascular endothelial growth factor per platelet count had significantly shorter progression-free survival and overall survival.
  
  
  CONCLUSIONS
  Bone marrow plasma vascular endothelial growth factor level per platelet count might be associated with bone marrow invasion by diffuse large B-cell lymphoma and is correlated with clinical outcomes after treatment.
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
authors.forename: Jung Sun
authors.initials: JS
authors.lastname: Kim
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
authors.forename: Ga Won
authors.initials: GW
authors.lastname: Gang
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
authors.forename: Se Ryun
authors.initials: SR
authors.lastname: Lee
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
authors.forename: Hwa Jung
authors.initials: HJ
authors.lastname: Sung
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
authors.forename: Young
authors.initials: Y
authors.lastname: Park
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
authors.forename: Dae Sik
authors.initials: DS
authors.lastname: Kim
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
authors.forename: Chul Won
authors.initials: CW
authors.lastname: Choi
authors.affiliation: Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea kbs0309@korea.ac.kr.
authors.forename: Byung Soo
authors.initials: BS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010976:Platelet Count; D011237:Predictive Value of Tests; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D015203:Reproducibility of Results; D000069283:Rituximab / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D042461:Vascular Endothelial Growth Factor A; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone
keywords: bone marrow; diffuse large B-cell lymphoma; platelet count; vascular endothelial growth factor